TY  - GEN
AU  - Adams,Christopher M
AU  - Anderson,Karen
AU  - Artman,Gerald
AU  - Bizec,Jean-Claude
AU  - Cepeda,Rosemarie
AU  - Elliott,Jason
AU  - Fassbender,Elizabeth
AU  - Ghosh,Malay
AU  - Hanks,Shawn
AU  - Hardegger,Leo A
AU  - Hosagrahara,Vinayak P
AU  - Jaffee,Bruce
AU  - Jendza,Keith
AU  - Ji,Nan
AU  - Johnson,Leland
AU  - Lee,Wendy
AU  - Liu,Donglei
AU  - Liu,Fang
AU  - Long,Debby
AU  - Ma,Fupeng
AU  - Mainolfi,Nello
AU  - Meredith,Erik L
AU  - Miranda,Karl
AU  - Peng,Yao
AU  - Poor,Stephen
AU  - Powers,James
AU  - Qiu,Yubin
AU  - Rao,Chang
AU  - Shen,Siyuan
AU  - Sivak,Jeremy M
AU  - Solovay,Catherine
AU  - Tarsa,Peter
AU  - Woolfenden,Amber
AU  - Zhang,Chun
AU  - Zhang,Yiqin
TI  - The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
SN  - 1520-4804
PY  - 2019///0415
KW  - Administration, Topical
KW  - Animals
KW  - Choroidal Neovascularization
KW  - Drug Discovery
KW  - Indoles
KW  - administration & dosage
KW  - Ophthalmic Solutions
KW  - Protein Kinase Inhibitors
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Rabbits
KW  - Rodentia
KW  - Structure-Activity Relationship
KW  - Vascular Endothelial Growth Factor Receptor-2
KW  - antagonists & inhibitors
KW  - Wet Macular Degeneration
KW  - drug therapy
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1021/acs.jmedchem.7b01731
ER  -